statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medical oncologist brings over 25 years of industry experience to lead Clinical Development StrategyBOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA...

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported...

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Highlights TTX-MC138's Path from Target Discovery to the ClinicBOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more...

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported...

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the Company ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics...

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Looking Into TransCode Therapeutics's Recent Short Interest

Project to test combination of TransCode's proprietary TTX delivery platform and Debiopharm's drug delivery technologiesBOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc...

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the Company ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics...

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the Company ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics...

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ  Free Report) are going to reverse split before the market opens on Tuesday, January 16th. The 1-40 reverse split was announced on Tuesday...

TransCode Therapeutics Stock Scheduled to Reverse Split on Tuesday, January 16th (NASDAQ:RNAZ)

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Watchers	5,558
52-Wk Low	$0.42
52-Wk High	$309.60

Volume	1.06M
52-Wk High	$309.60
52-Wk Low	$0.42

RNAZ TransCode Therapeutics Inc

About

Feed

News

Fundamentals